Timing of invasive septal reduction therapies and outcome of patients with obstructive hypertrophic cardiomyopathy. (15th December 2018)

• Record Type: Journal Article
• Authors: Cavigli, Luna; Fumagalli, Carlo; Maurizi, Niccolò; Rossi, Alessandra; Arretini, Anna; Targetti, Mattia; Passantino, Silvia; Girolami, Francesca; Tomberli, Benedetta; Baldini, Katia; Tomberli, Alessia; Antoniucci, David; Yacoub, Magdi H.; Marchionni, Niccolò; Stefano, Pier Luigi; Cecchi, Franco; Olivotto, Iacopo
• Is Part Of: International journal of cardiology. Volume 273(2018)
• Page Start: 155
• Page End: 161
• Publication Date: 2018-12-15
• Subjects: ASA alcohol septal ablation -- CV cardiovascular -- HOCM hypertrophic obstructive cardiomyopathy -- LAD left atrial diameter -- LVOT Left ventricular outflow tract -- LVOTO Left ventricular outflow tract obstruction -- NYHA New York Heart Association functional class -- SAM systolic anterior motion -- SM septal myectomy -- SRT septal reduction therapies -- TTT time-to-treatment; Timing -- Surgical myectomy -- Alcohol septal ablation -- Septal reduction therapies -- Hypertrophic obstructive cardiomyopathy -- Outcome; Cardiology -- Periodicals; Electronic journals; 616.12
• DOI: 10.1016/j.ijcard.2018.09.004
• Languages: English
• ISSNs: 0167-5273

Abstract

Abstract: Background: Whether early vs. delayed referral to septal reduction therapies (SRT, alcohol septal ablation or surgical myectomy) bears prognostic relevance in hypertrophic obstructive cardiomyopathy (HOCM) is unresolved. We analyzed the impact of SRT timing on the outcome of HOCM patients. Methods: We followed 126 patients for 5 ± 4 years after SRT (mean age 53 ± 15 years; 55 post-ASA and 71 post-SM). Based on time-to-treatment (TTT; from HOCM diagnosis to SRT), patients were divided into three groups: "<3" years, N = 50; "3–5" years, N = 25; ">5" years, N = 51. Results: Patients with TTT > 5 years were younger at diagnosis and more often had atrial fibrillation (AF). Left ventricular outflow tract (LVOT) gradients were comparable in the 3 TTT groups. Two patients died peri-operatively, all with TTT > 5. Long-term, 8 patients died (3 suddenly and 5 due to heart failure). Mortality increased progressively with TTT (2% vs. 4% vs. 12% for TTT "<3", "3–5", and ">5" years, p for trend = 0.039). Independent predictors of disease progression (new-onset AF, worsening to NYHA III/IV symptoms, re-intervention or death) were TTT ("3–5" vs. "<3" years: HR: 4.988, 95%CI: 1.394–17.843; ">5" vs. "<3" years: HR: 3.420, 95%CI: 1.258–9.293, overall p-value = 0.025), AF at baseline (HR: 1.896, 95%CI: 1.002–3.589, p = 0.036) and LVOT gradient (HR per mm Hg increase: 1.022, 95%CI: 1.007–1.024, p = 0.023). Conclusions: Delay in SRT referral has significant impact on long-term outcome of patients with HOCM, particularly when >5 years from first detection of gradient, even when successful relief of symptoms and gradient is achieved. Earlier interventions are associated with lower complication rates and better prognosis, suggesting the importance of timely SRT to maximize treatment benefit and prevent late HOCM-related complications. Highlights: Delayed Septal Reduction Therapies are associated with increased cardiovascular mortality and disease progression in HOCM. Such disadvantage is particularly evident if time between detection of dynamic obstruction and intervention exceeds 5 years. Intervention should be discussed early in patients with severe obstruction and, if indicated, not delayed more than 5 years.